Evaluation of the Efficacy and Safety of Endoscopic Dilatation and Biological Therapy in Intestinal Stenosis Due to CD
NCT ID: NCT06603298
Last Updated: 2024-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
182 participants
OBSERVATIONAL
2024-10-17
2025-10-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All clinical data will be recorded for all patients:
* Demographic data (age, sex, smoking habits)
* Montreal classification;
* Duration of disease;
* History of previous surgery;
* Past and current drug therapy.
All available data on stenosis characteristics will be recorded:
* Localisation (ileal, ileo-caecal, colic, anastomotic);
* Extent (mm);
* Evidence of concurrent endoscopic disease activity locally
All data related to the endoscopic procedure will also be recorded:
* Size of device used;
* Maximum dilatation achieved (mm);
* Technical success, assessed by endoscopic clearance of the stenosis after the dilation procedure;
* Consensual local steroid injection;
* Possible multiple endoscopic dilation sessions;
The occurrence of episodes of intestinal sub-occlusion or occlusion will be recorded, the introduction of steroid therapy and the need for surgery. Where available radiological and endoscopic re-evaluation data will be recorded.
Any changes in treatment and any adverse events, defined as any adverse event, will also be recorded. as any adverse event without a necessary causal relationship with the endoscopic procedure and the concomitant ongoing biological therapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Medical therapy alone
It includes patients with Crohn's disease who were only treated with biological therapy for clinically significant intestinal stenosis. These patients underwent drug treatment without any endoscopic procedure.
No interventions assigned to this group
Medical therapy + endoscopic dilatation
It includes patients who received both endoscopic dilatation (ED) with a balloon and biological therapy. This cohort underwent combined treatment for intestinal stenosis, integrating mechanical and pharmacological intervention.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of Crohn\'s disease;
* Radiological or endoscopic evidence of Crohn\'s disease complicated by clinically significant intestinal stenosis treated by endoscopic balloon dilatation.
* Minimum 12-month clinical follow-up at this hospital;
* Ability to express and give informed consent for participation in the study and to adhere to the timetable of scheduled visits.
Exclusion Criteria
* Patients with pouch or terminal ileostomy;
* Any clinical condition that, in the opinion of the investigators, may contraindicate enrolment in the study;
* Unstable personality or inability to adhere to protocol procedures;
* Inability to express and give informed consent for study participation and to adhere to the participation in the study and to adhere to the timing of the planned visits.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Franco Scaldaferri, PI
Role: PRINCIPAL_INVESTIGATOR
Fondazione Policlinico Gemelli, Rome
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC CEMAD
Roma, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ENDO_BIO- CROHN- ID 6815
Identifier Type: -
Identifier Source: org_study_id